Want to see JP:4576 full AI Analyst Report?
4576 Stock Chart & Stats
¥105.00
-¥3.00(-1.74%)
At close: 4:00 PM EST
¥105.00
-¥3.00(-1.74%)
Day’s Range― - ―
52-Week Range¥66.00 - ¥181.00
Previous CloseN/A
Volume3.18M
Average Volume (3M)623.89K
Market Cap
¥4.48B
Enterprise Value¥2.55B
Total Cash (Recent Filing)¥1.54B
Total Debt (Recent Filing)¥594.17M
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.89
Shares Outstanding57,483,414
10 Day Avg. Volume615,690
30 Day Avg. Volume623,886
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.21
Price to Sales (P/S)11.87
P/FCF Ratio-9.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustainably high gross margins reflect favorable product economics and potential pricing power. Over a 2–6 month horizon these margins provide structural insulation against revenue volatility, enabling the firm to allocate more of incremental sales to R&D or SG&A and shortening the path to break-even if operating expenses are managed.
Improved LeverageMaterial deleveraging in 2025 meaningfully lowers solvency risk and interest exposure. This durable improvement enhances financial flexibility over months, reducing refinancing pressure and making the balance sheet better able to weather continued losses while supporting strategic choices like committed R&D spend or selective partnerships.
Narrowing Losses / Improving BurnA tangible reduction in losses and an improved cash burn trend signal better cost control or operational execution. If sustained over the next several quarters, this trend increases the credibility of management's ability to stabilize operations and extends runway, lowering the immediacy of external funding needs.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the business cannot self-fund operations and remains dependent on external capital. Over 2–6 months this elevates dilution and refinancing risk, constrains strategic investments, and limits the firm's ability to absorb setbacks or accelerate commercial programs without new funding.
Deep UnprofitabilityNet losses that exceed revenue represent a structural profitability deficit. Persisting at this scale erodes equity and produces negative returns on capital, limiting reinvestment and partnership attractiveness. Over a multi-month horizon this undermines ability to achieve self-sustaining growth without material operational change or new revenue streams.
Small, Volatile Revenue BaseA small, volatile top line restricts predictability and scale economics. Over 2–6 months this reduces the company's ability to leverage its high gross margins into sustained profitability, increases dependence on financing, and complicates planning for commercialization or long-term R&D projects given uncertain near-term cash receipts.
D.Western Therapeutics Institute News
4576 FAQ
What was D.Western Therapeutics Institute, Inc.’s price range in the past 12 months?
D.Western Therapeutics Institute, Inc. lowest stock price was ¥66.00 and its highest was ¥181.00 in the past 12 months.
What is D.Western Therapeutics Institute, Inc.’s market cap?
D.Western Therapeutics Institute, Inc.’s market cap is ¥4.48B.
When is D.Western Therapeutics Institute, Inc.’s upcoming earnings report date?
D.Western Therapeutics Institute, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 18 days.
How were D.Western Therapeutics Institute, Inc.’s earnings last quarter?
D.Western Therapeutics Institute, Inc. released its earnings results on May 14, 2026. The company reported -¥3.14 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.14.
Is D.Western Therapeutics Institute, Inc. overvalued?
According to Wall Street analysts D.Western Therapeutics Institute, Inc.’s price is currently Overvalued.
Does D.Western Therapeutics Institute, Inc. pay dividends?
D.Western Therapeutics Institute, Inc. does not currently pay dividends.
What is D.Western Therapeutics Institute, Inc.’s EPS estimate?
D.Western Therapeutics Institute, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does D.Western Therapeutics Institute, Inc. have?
D.Western Therapeutics Institute, Inc. has 57,483,414 shares outstanding.
What happened to D.Western Therapeutics Institute, Inc.’s price movement after its last earnings report?
D.Western Therapeutics Institute, Inc. reported an EPS of -¥3.14 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of D.Western Therapeutics Institute, Inc.?
Currently, no hedge funds are holding shares in JP:4576
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
D.Western Therapeutics Institute, Inc.
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.